209 related articles for article (PubMed ID: 26478752)
1. High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer.
Strand SH; Hoyer S; Lynnerup AS; Haldrup C; Storebjerg TM; Borre M; Orntoft TF; Sorensen KD
Clin Epigenetics; 2015; 7():111. PubMed ID: 26478752
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer.
Storebjerg TM; Strand SH; Høyer S; Lynnerup AS; Borre M; Ørntoft TF; Sørensen KD
Clin Epigenetics; 2018 Aug; 10(1):105. PubMed ID: 30086793
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.
Nørgaard M; Haldrup C; Storebjerg TM; Vestergaard EM; Wild PJ; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28930171
[TBL] [Abstract][Full Text] [Related]
4. 5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors.
Kristensen G; Strand SH; Røder MA; Berg KD; Toft BG; Høyer S; Borre M; Sørensen KD; Brasso K
Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30818754
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
[TBL] [Abstract][Full Text] [Related]
6. RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
Strand SH; Switnicki M; Moller M; Haldrup C; Storebjerg TM; Hedegaard J; Nordentoft I; Hoyer S; Borre M; Pedersen JS; Wild PJ; Park JY; Orntoft TF; Sorensen KD
Oncotarget; 2017 Jan; 8(4):5774-5788. PubMed ID: 28052017
[TBL] [Abstract][Full Text] [Related]
7. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer.
Haldrup C; Mundbjerg K; Vestergaard EM; Lamy P; Wild P; Schulz WA; Arsov C; Visakorpi T; Borre M; Høyer S; Orntoft TF; Sørensen KD
J Clin Oncol; 2013 Sep; 31(26):3250-8. PubMed ID: 23918943
[TBL] [Abstract][Full Text] [Related]
9. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy.
Rubio-Briones J; Fernández-Serra A; Calatrava A; García-Casado Z; Rubio L; Bonillo MA; Iborra I; Solsona E; López-Guerrero JA
J Urol; 2010 May; 183(5):2054-61. PubMed ID: 20303538
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.
Kim SH; Kim SH; Joung JY; Lee GK; Hong EK; Kang KM; Yu A; Nam BH; Chung J; Seo HK; Park WS; Lee KH
PLoS One; 2015; 10(4):e0122498. PubMed ID: 25897494
[TBL] [Abstract][Full Text] [Related]
11. Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.
Kristensen H; Thomsen AR; Haldrup C; Dyrskjøt L; Høyer S; Borre M; Mouritzen P; Ørntoft TF; Sørensen KD
Oncotarget; 2016 May; 7(21):30760-71. PubMed ID: 27120795
[TBL] [Abstract][Full Text] [Related]
12. Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy.
Fajkovic H; Mathieu R; Lucca I; Hiess M; Hübner N; Al Hussein Al Awamlh B; Lee R; Briganti A; Karakiewicz P; Lotan Y; Roupret M; Rink M; Kluth L; Loidl W; Seitz C; Klatte T; Kramer G; Susani M; Shariat SF
Urol Oncol; 2016 May; 34(5):233.e1-6. PubMed ID: 26973136
[TBL] [Abstract][Full Text] [Related]
13. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
14. Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels.
Haldrup C; Lynnerup AS; Storebjerg TM; Vang S; Wild P; Visakorpi T; Arsov C; Schulz WA; Lindberg J; Grönberg H; Egevad L; Borre M; Ørntoft TF; Høyer S; Sørensen KD
Mol Oncol; 2016 Jun; 10(6):825-37. PubMed ID: 26905753
[TBL] [Abstract][Full Text] [Related]
15. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair.
Dal Pra A; Lalonde E; Sykes J; Warde F; Ishkanian A; Meng A; Maloff C; Srigley J; Joshua AM; Petrovics G; van der Kwast T; Evans A; Milosevic M; Saad F; Collins C; Squire J; Lam W; Bismar TA; Boutros PC; Bristow RG
Clin Cancer Res; 2013 Sep; 19(18):5202-9. PubMed ID: 23918607
[TBL] [Abstract][Full Text] [Related]
16. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
17. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
18. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer.
Kron K; Liu L; Trudel D; Pethe V; Trachtenberg J; Fleshner N; Bapat B; van der Kwast T
Clin Cancer Res; 2012 May; 18(10):2896-904. PubMed ID: 22452941
[TBL] [Abstract][Full Text] [Related]
19. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
[TBL] [Abstract][Full Text] [Related]
20. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
